p73 is over-expressed in vulval cancer principally as the Delta 2 isoform
p73 was studied in squamous cancers and precursor lesions of the vulva. Over-expression of p73 occurred commonly in both human papillomavirus (HPV)-positive and -negative squamous cell cancers (SCC) and high-grade premalignant lesions. Whereas expression in normal vulval epithelium was detected only in the basal and supra-basal layers, expression in neoplastic epithelium increased with grade of neoplasia, being maximal at both protein and RNA levels in SCC. p73 Delta 2 was the principal over-expressed isoform in the majority of cases of vulval SCC and often the sole form expressed in SCC. Over-expression of p73 was associated with expression of HPV-encoded E7 or with hypermethylation or mutation of p16(INK4a) in HPV-negative cases. There was a close correlation between expression of p73 and p14(ARF) in cancers with loss of p53 function. The frequent over-expression of p73 Delta 2 in neoplastic but not normal vulval epithelium, and its co-ordinate deregulation with other E2F-1 responsive genes suggests a role in the oncogenic process.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2001 |
|---|---|
| Erschienen: |
2001 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:85 |
|---|---|
| Enthalten in: |
British journal of cancer - 85(2001), 10 vom: 16. Nov., Seite 1551-6 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
O'Nions, J [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 14.02.2002 Date Revised 13.11.2020 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM116122595 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM116122595 | ||
| 003 | DE-627 | ||
| 005 | 20231222173643.0 | ||
| 007 | tu | ||
| 008 | 231222s2001 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0387.xml |
| 035 | |a (DE-627)NLM116122595 | ||
| 035 | |a (NLM)11720444 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a O'Nions, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a p73 is over-expressed in vulval cancer principally as the Delta 2 isoform |
| 264 | 1 | |c 2001 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2002 | ||
| 500 | |a Date Revised 13.11.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a p73 was studied in squamous cancers and precursor lesions of the vulva. Over-expression of p73 occurred commonly in both human papillomavirus (HPV)-positive and -negative squamous cell cancers (SCC) and high-grade premalignant lesions. Whereas expression in normal vulval epithelium was detected only in the basal and supra-basal layers, expression in neoplastic epithelium increased with grade of neoplasia, being maximal at both protein and RNA levels in SCC. p73 Delta 2 was the principal over-expressed isoform in the majority of cases of vulval SCC and often the sole form expressed in SCC. Over-expression of p73 was associated with expression of HPV-encoded E7 or with hypermethylation or mutation of p16(INK4a) in HPV-negative cases. There was a close correlation between expression of p73 and p14(ARF) in cancers with loss of p53 function. The frequent over-expression of p73 Delta 2 in neoplastic but not normal vulval epithelium, and its co-ordinate deregulation with other E2F-1 responsive genes suggests a role in the oncogenic process | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Cyclin-Dependent Kinase Inhibitor p16 |2 NLM | |
| 650 | 7 | |a DNA-Binding Proteins |2 NLM | |
| 650 | 7 | |a Nuclear Proteins |2 NLM | |
| 650 | 7 | |a Oncogene Proteins, Viral |2 NLM | |
| 650 | 7 | |a Papillomavirus E7 Proteins |2 NLM | |
| 650 | 7 | |a Protein Isoforms |2 NLM | |
| 650 | 7 | |a RNA, Neoplasm |2 NLM | |
| 650 | 7 | |a TP73 protein, human |2 NLM | |
| 650 | 7 | |a Tumor Protein p73 |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Protein p14ARF |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Protein p53 |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Proteins |2 NLM | |
| 650 | 7 | |a oncogene protein E7, Human papillomavirus type 16 |2 NLM | |
| 700 | 1 | |a Brooks, L A |e verfasserin |4 aut | |
| 700 | 1 | |a Sullivan, A |e verfasserin |4 aut | |
| 700 | 1 | |a Bell, A |e verfasserin |4 aut | |
| 700 | 1 | |a Dunne, B |e verfasserin |4 aut | |
| 700 | 1 | |a Rozycka, M |e verfasserin |4 aut | |
| 700 | 1 | |a Reddy, A |e verfasserin |4 aut | |
| 700 | 1 | |a Tidy, J A |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, D |e verfasserin |4 aut | |
| 700 | 1 | |a Farrell, P J |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, A |e verfasserin |4 aut | |
| 700 | 1 | |a Gasco, M |e verfasserin |4 aut | |
| 700 | 1 | |a Gusterson, B |e verfasserin |4 aut | |
| 700 | 1 | |a Crook, T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of cancer |d 1947 |g 85(2001), 10 vom: 16. Nov., Seite 1551-6 |w (DE-627)NLM000027537 |x 1532-1827 |7 nnns |
| 773 | 1 | 8 | |g volume:85 |g year:2001 |g number:10 |g day:16 |g month:11 |g pages:1551-6 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 85 |j 2001 |e 10 |b 16 |c 11 |h 1551-6 | ||